Nanoniosome-based drug codelivery systems have become popular therapeutic instruments, demonstrating tremendous promise in cancer therapy, infection treatment, and other therapeutic domains. An emerging form of vesicular nanocarriers, niosomes are self-assembling vesicles composed of nonionic surfactants, along with cholesterol or other amphiphilic molecules. This comprehensive review focuses on how nanosystems may aid in making anticancer and antibacterial pharmaceuticals more stable and soluble. As malleable nanodelivery instruments, the composition, types, preparation procedures, and variables affecting the structure and stability of niosomes are extensively investigated. In addition, the advantages of dual niosomes for combination therapy and the administration of multiple medications simultaneously are highlighted. Along with categorizing niosomal drug delivery systems, a comprehensive analysis of various preparation techniques, including thin-layer injection, ether injection, and microfluidization, is provided. Dual niosomes for cancer treatment are discussed in detail regarding the codelivery of two medications and the codelivery of a drug with organic, plant-based bioactive compounds or gene agents. In addition, niogelosomes and metallic niosomal carriers for targeted distribution are discussed. The review also investigates the simultaneous delivery of bioactive substances and gene agents, including siRNA, microRNA, shRNA, lncRNA, and DNA. Additional sections discuss the use of dual niosomes for cutaneous drug delivery and treating leishmanial infections, Pseudomonas aeruginosa, and Mycobacterium tuberculosis. The study concludes by delineating the challenges and potential routes for nanoniosome-based pharmaceutical codelivery systems, which will be useful for nanomedicine practitioners and researchers.

A chemically modified carbon paste electrode, based on a CoMOF-graphene oxide (GO) and an ionic liquid of 1-methyl-3-butylimidazolium bromide (CoMOF-GO/1-M,3-BB/CPE), was fabricated for the simultaneous determination of dopamine (DA) and uric acid (UA). The prepared CoMOF/GO nanocomposite was characterized by field emission-scanning electron microscopy (FE-SEM), the X-ray diffraction (XRD) method, a N₂ adsorption–desorption isotherm, and an energy dispersive spectrometer (EDS). The electrochemical sensor clearly illustrated catalytic activity towards the redox reaction of dopamine (DA), which can be authenticated by comparing the increased oxidation peak current with the bare carbon paste electrode. The CoMOF-GO/1-M,3-BB/CPE exhibits a wide linear response for DA in the concentration range of 0.1 to 300.0 µM, with a detection limit of 0.04 µM. The oxidation peaks’ potential for DA and uric acid (UA) were separated well in the mixture containing the two compounds. This study demonstrated a simple and effective method for detecting DA and UA in real samples.